Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
Start Date
4/13/2023
Completion Date
7/1/2031
Summary
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Daily adaptive SBRT with urethral sparing
Conditions
Locations
Duarte Cancer Center
Duarte, California 91010
United States
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California 92618
United States
Brigham and Women's Hospital
Boston, Massachusetts 02115
United States
Washington University in St. Louis
St Louis, Missouri 63110
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania 19111
United States
Klinikum der Landeshauptstadt Stuttgart gKAöR
Stuttgart, Baden-Wurttemberg 70174
Germany
Universitätsklinikum des Saarlandes (Saarland Univerisity Hospital)
Homburg, Saarland 66421
Germany
Hospital Universitario de Navarra
Pamplona, Navarre 31008
Spain